Addressing Comorbidities in Heart Failure: Hypertension, Atrial Fibrillation, and Diabetes

Overview

Journal Heart Fail Clin

Specialty Cardiology & Vascular Diseases

Date 2020 Sep 5

PMID 32888639

Citations 8

Authors

Aakash Bavishi

Ravi B Patel

Affiliations

Soon will be listed here.

Abstract

Heart failure (HF) is a growing global epidemic and an increasingly cumbersome burden on health care systems worldwide. As such, optimal management of existing comorbidities in the setting of HF is particularly important to prevent disease progression, reduce HF hospitalizations, and improve quality of life. In this review, the authors address 3 key comorbidities commonly associated with HF: hypertension, atrial fibrillation, and diabetes mellitus. They comprehensively describe the epidemiology, management, and emerging therapies in these 3 disease states as they relate to the overall HF syndrome.

Citing Articles

Exploring the Relationship Between Ejection Fraction, Arterial Stiffness, NT-proBNP, and Hospitalization Risk in Heart Failure Patients.

Osser G, Osser B, Toth C, Miuta C, Marconi G, Bondar L Diagnostics (Basel). 2025; 14(24.

PMID: 39767246 PMC: 11675150. DOI: 10.3390/diagnostics14242885.

Disease Network-Based Approaches to Study Comorbidity in Heart Failure: Current State and Future Perspectives.

Gomez-Ochoa S, Lanzer J, Levinson R Curr Heart Fail Rep. 2024; 22(1):6.

PMID: 39725810 PMC: 11671564. DOI: 10.1007/s11897-024-00693-7.

Real-Life Individual Comparison of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Heart Failure and Diabetes Mellitus.

Yilmaz M, Celik A, Colluoglu T, Sahin A, Ural D, Kanik A Am J Cardiovasc Drugs. 2024; 25(2):277-286.

PMID: 39609352 DOI: 10.1007/s40256-024-00698-6.

Socioeconomic Gender Variables Impact the Association between Hypertension and Chronic Health Issues: Cross-Sectional Study.

Lindner S, Gisinger T, Klimek P, Kautzky-Willer A J Pers Med. 2024; 14(8).

PMID: 39202081 PMC: 11355497. DOI: 10.3390/jpm14080890.

Precision Cardiology: Phenotype-targeted Therapies for HFmrEF and HFpEF.

Rosano G, Vitale C, Spoletini I Int J Heart Fail. 2024; 6(2):47-55.

PMID: 38694928 PMC: 11058434. DOI: 10.36628/ijhf.2023.0058.

References

Kasai T, Bradley T . Obstructive sleep apnea and heart failure: pathophysiologic and therapeutic implications. J Am Coll Cardiol. 2011; 57(2):119-27. DOI: 10.1016/j.jacc.2010.08.627. View

Kotecha D, Lam C, Van Veldhuisen D, Van Gelder I, Voors A, Rienstra M . Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation: Vicious Twins. J Am Coll Cardiol. 2016; 68(20):2217-2228. DOI: 10.1016/j.jacc.2016.08.048. View

Moller M, Torp-Pedersen C, Kober L . Dofetilide in patients with congestive heart failure and left ventricular dysfunction: safety aspects and effect on atrial fibrillation. The Danish Investigators of Arrhythmia and Mortality on Dofetilide (DIAMOND) Study Group. . Congest Heart Fail. 2002; 7(3):146-150. DOI: 10.1111/j.1527-5299.2001.00243.x. View

Hunter R, Berriman T, Diab I, Kamdar R, Richmond L, Baker V . A randomized controlled trial of catheter ablation versus medical treatment of atrial fibrillation in heart failure (the CAMTAF trial). Circ Arrhythm Electrophysiol. 2014; 7(1):31-8. DOI: 10.1161/CIRCEP.113.000806. View

Ekeruo I, Solhpour A, Taegtmeyer H . Metformin in Diabetic Patients with Heart Failure: Safe and Effective?. Curr Cardiovasc Risk Rep. 2014; 7(6):417-422. PMC: 3899937. DOI: 10.1007/s12170-013-0355-4. View

Savarese G, Lund L . Global Public Health Burden of Heart Failure. Card Fail Rev. 2017; 3(1):7-11. PMC: 5494150. DOI: 10.15420/cfr.2016:25:2. View

Savarese G, Giugliano R, Rosano G, McMurray J, Magnani G, Filippatos G . Efficacy and Safety of Novel Oral Anticoagulants in Patients With Atrial Fibrillation and Heart Failure: A Meta-Analysis. JACC Heart Fail. 2016; 4(11):870-880. DOI: 10.1016/j.jchf.2016.07.012. View

Santhanakrishnan R, Wang N, Larson M, Magnani J, McManus D, Lubitz S . Atrial Fibrillation Begets Heart Failure and Vice Versa: Temporal Associations and Differences in Preserved Versus Reduced Ejection Fraction. Circulation. 2016; 133(5):484-92. PMC: 4738087. DOI: 10.1161/CIRCULATIONAHA.115.018614. View

Levy D, Kenchaiah S, Larson M, Benjamin E, Kupka M, Ho K . Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002; 347(18):1397-402. DOI: 10.1056/NEJMoa020265. View

10.

Ling L, Kistler P, Kalman J, Schilling R, Hunter R . Comorbidity of atrial fibrillation and heart failure. Nat Rev Cardiol. 2015; 13(3):131-47. DOI: 10.1038/nrcardio.2015.191. View

11.

Patel R, Vaduganathan M, Rikhi A, Chakraborty H, Greene S, Hernandez A . History of Atrial Fibrillation and Trajectory of Decongestion in Acute Heart Failure. JACC Heart Fail. 2018; 7(1):47-55. PMC: 6320310. DOI: 10.1016/j.jchf.2018.09.008. View

12.

Yusuf S, Pitt B, Davis C, Hood Jr W, Cohn J . Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992; 327(10):685-91. DOI: 10.1056/NEJM199209033271003. View

13.

Levy D, Larson M, Vasan R, Kannel W, Ho K . The progression from hypertension to congestive heart failure. JAMA. 1996; 275(20):1557-62. View

14.

Allen L, Magid D, Gurwitz J, Smith D, Goldberg R, Saczynski J . Risk factors for adverse outcomes by left ventricular ejection fraction in a contemporary heart failure population. Circ Heart Fail. 2013; 6(4):635-46. PMC: 3826979. DOI: 10.1161/CIRCHEARTFAILURE.112.000180. View

15.

Zafrir B, Lund L, Laroche C, Ruschitzka F, Crespo-Leiro M, Coats A . Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term Registry. Eur Heart J. 2018; 39(48):4277-4284. DOI: 10.1093/eurheartj/ehy626. View

16.

Kelly J, DeVore A, Wu J, Hammill B, Sharma A, Cooper L . Rhythm Control Versus Rate Control in Patients With Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction: Insights From Get With The Guidelines-Heart Failure. J Am Heart Assoc. 2019; 8(24):e011560. PMC: 6951063. DOI: 10.1161/JAHA.118.011560. View

17.

White W, Cannon C, Heller S, Nissen S, Bergenstal R, Bakris G . Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013; 369(14):1327-35. DOI: 10.1056/NEJMoa1305889. View

18.

Wiviott S, Raz I, Bonaca M, Mosenzon O, Kato E, Cahn A . Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2018; 380(4):347-357. DOI: 10.1056/NEJMoa1812389. View

19.

Zannad F, Cannon C, Cushman W, Bakris G, Menon V, Perez A . Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015; 385(9982):2067-76. DOI: 10.1016/S0140-6736(14)62225-X. View

20.

Vaduganathan M, Patel R, Singh A, McCarthy C, Qamar A, Januzzi Jr J . Prescription of Glucagon-Like Peptide-1 Receptor Agonists by Cardiologists. J Am Coll Cardiol. 2019; 73(12):1596-1598. PMC: 6764415. DOI: 10.1016/j.jacc.2019.01.029. View